Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2014, Article ID 260613, 10 pages
http://dx.doi.org/10.1155/2014/260613
Research Article

A Tandem Repeat in Decay Accelerating Factor 1 Is Associated with Severity of Murine Mercury-Induced Autoimmunity

1Department of Surgery, University of California, San Diego, 9500 Gilman Drive, No. 0739, La Jolla, CA 92093-0739, USA
2Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
3Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
4Molecular and Immunological Pathology, Department of Experimental and Clinical Medicine, Linköping University, 581 83 Linköping, Sweden

Received 4 January 2014; Accepted 21 February 2014; Published 10 April 2014

Academic Editor: Aristo Vojdani

Copyright © 2014 David M. Cauvi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Lublin and J. P. Atkinson, “Decay-accelerating factor: biochemistry, molecular biology, and function,” Annual Review of Immunology, vol. 7, pp. 35–58, 1989. View at Google Scholar · View at Scopus
  2. W.-C. Song, “Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury,” Current Directions in Autoimmunity, vol. 7, pp. 181–199, 2004. View at Google Scholar · View at Scopus
  3. P. S. Heeger, P. N. Lalli, F. Lin et al., “Decay-accelerating factor modulates induction of T cell immunity,” Journal of Experimental Medicine, vol. 201, no. 10, pp. 1523–1530, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Liu, T. Miwa, B. Hilliard et al., “The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo,” Journal of Experimental Medicine, vol. 201, no. 4, pp. 567–577, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Longhi, C. L. Harris, B. P. Morgan, and A. Gallimore, “Holding T cells in check—a new role for complement regulators?” Trends in Immunology, vol. 27, no. 2, pp. 102–108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. W.-C. Song, “Complement regulatory proteins and autoimmunity,” Autoimmunity, vol. 39, no. 5, pp. 403–410, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. T. W. Post, M. A. Arce, M. K. Liszewski, E. S. Thompson, J. P. Atkinson, and D. M. Lublin, “Structure of the gene for human complement protein decay accelerating factor,” Journal of Immunology, vol. 144, no. 2, pp. 740–744, 1990. View at Google Scholar · View at Scopus
  8. A. P. Spicer, M. F. Seldin, and S. J. Gendler, “Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes: duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms,” Journal of Immunology, vol. 155, no. 6, pp. 3079–3091, 1995. View at Google Scholar · View at Scopus
  9. F. Lin, Y. Fukuoka, A. Spicer et al., “Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies,” Immunology, vol. 104, no. 2, pp. 215–225, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. D. J. Thomas and D. M. Lublin, “Identification of 5'-flanking regions affecting the expression of the human decay accelerating factor gene and their role in tissue-specific expression,” Journal of Immunology, vol. 150, no. 1, pp. 151–160, 1993. View at Google Scholar · View at Scopus
  11. A. Nicholson-Weller, J. P. March, and C. E. Rosen, “Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system,” Blood, vol. 65, no. 5, pp. 1237–1244, 1985. View at Google Scholar · View at Scopus
  12. M. E. Medof, E. I. Walter, and J. L. Rutgers, “Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids,” Journal of Experimental Medicine, vol. 165, no. 3, pp. 848–864, 1987. View at Google Scholar · View at Scopus
  13. O. B. Spiller, O. Criado-Garcia, S. Rodriguez de Cordoba, and B. P. Morgan, “Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack,” Clinical and Experimental Immunology, vol. 121, no. 2, pp. 234–241, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. E. T. Cocuzzi, D. Bardenstyein, A. Stavitsky, N. Sudarraj, and M. E. Medof, “Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-β and TNF-α,” Current Eye Research, vol. 23, no. 2, pp. 86–92, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. S. R. Ahmad, E. A. Lidington, R. Ohta et al., “Decay-accelerating factor induction by tumour necrosis factor-α, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition,” Immunology, vol. 110, no. 2, pp. 258–268, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. V. R. Holla, D. Wang, J. R. Brown, J. R. Mann, S. Katkuri, and R. N. DuBois, “Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer,” Journal of Biological Chemistry, vol. 280, no. 1, pp. 476–483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Andoh, K. Kinoshita, I. Rosenberg, and D. K. Podolsky, “Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells,” Journal of Immunology, vol. 167, no. 7, pp. 3887–3893, 2001. View at Google Scholar · View at Scopus
  18. J. Saklatvala, J. Dean, and A. Clark, “Control of the expression of inflammatory response genes,” Biochemical Society Symposium, no. 70, pp. 95–106, 2003. View at Google Scholar · View at Scopus
  19. G. Kendall, H. Crankson, E. Ensor et al., “Activation of the gene encoding decay accelerating factor following nerve growth factor treatment of sensory neurons is mediated by promoter sequences within 206 bases of the transcriptional start site,” Journal of Neuroscience Research, vol. 45, no. 2, pp. 96–103, 1996. View at Google Scholar
  20. N. A. Louis, K. E. Hamilton, T. Kong, and S. P. Colgan, “HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils,” FASEB Journal, vol. 19, no. 8, pp. 950–959, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. U. K. Ewulonu, L. Ravi, and M. E. Medof, “Characterization of the decay-accelerating factor gene promoter region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 11, pp. 4675–4679, 1991. View at Google Scholar · View at Scopus
  22. D. M. Cauvi, G. Cauvi, and K. M. Pollard, “Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1,” Journal of Immunology, vol. 177, no. 6, pp. 3837–3847, 2006. View at Google Scholar · View at Scopus
  23. D. D. Kim and W. C. Song, “Membrane complement regulatory proteins,” Clinical Immunology, vol. 118, no. 2-3, pp. 127–136, 2006. View at Google Scholar
  24. D. M. Cauvi, G. Cauvi, and K. M. Pollard, “Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease,” Arthritis and Rheumatism, vol. 56, no. 6, pp. 1934–1944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Miwa, M. A. Maldonado, L. Zhou et al., “Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice,” American Journal of Pathology, vol. 161, no. 3, pp. 1077–1086, 2002. View at Google Scholar · View at Scopus
  26. C. B. Toomey, D. M. Cauvi, W.-C. Song, and K. M. Pollard, “Decay-accelerating factor 1 (Daf1) deficiency exacerbates xenobiotic-induced autoimmunity,” Immunology, vol. 131, no. 1, pp. 99–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. M. Cauvi, C. B. Toomey, and K. M. Pollard, “Depletion of complement does not impact initiation of xenobiotic-induced autoimmune disease,” Immunology, vol. 135, no. 4, pp. 333–343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Sogabe, M. Nangaku, Y. Ishibashi et al., “Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis,” Journal of Immunology, vol. 167, no. 5, pp. 2791–2797, 2001. View at Google Scholar · View at Scopus
  29. F. Lin, D. J. Salant, H. Meyerson, S. Emancipator, B. P. Morgan, and M. E. Medof, “Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis,” Journal of Immunology, vol. 172, no. 4, pp. 2636–2642, 2004. View at Google Scholar · View at Scopus
  30. F. Lin, H. J. Kaminski, B. M. Conti-Fine, W. Wang, C. Richmonds, and M. Edward Medof, “Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection,” Journal of Clinical Investigation, vol. 110, no. 9, pp. 1269–1274, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. D. H. Kono, M. S. Park, A. Szydlik et al., “Resistance to xenobiotic-induced autoimmunity maps to chromosome 1,” Journal of Immunology, vol. 167, no. 4, pp. 2396–2403, 2001. View at Google Scholar · View at Scopus
  32. M. H. Owens and B. Bonavida, “Immune functions characteristic of SJL/J mice and their association with age and spontaneous reticulum cell sarcoma,” Cancer Research, vol. 36, no. 3, pp. 1077–1083, 1976. View at Google Scholar · View at Scopus
  33. K. Kobayashi, T. Izawa, M. Kuwamura, and J. Yamate, “Comparative gene expression analysis in the skeletal muscles of dysferlin-defcient SJL/J and A/J mice,” Journal of Toxicologic Pathology, vol. 24, no. 1, pp. 49–62, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Relle and A. Schwarting, “Role of MHC-linked susceptibility genes in the pathogenesis of human and murine lupus,” Clinical and Developmental Immunology, vol. 2012, Article ID 584374, 15 pages, 2012. View at Publisher · View at Google Scholar
  35. P. Hultman, L. J. Bell, S. Enestrom, and K. M. Pollard, “Murine susceptibility to mercury. II. Autoantibody profiles and renal immune deposits in hybrid, backcross, and H-2d congenic mice,” Clinical Immunology and Immunopathology, vol. 68, no. 1, pp. 9–20, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. D. M. Cauvi, P. Hultman, and K. M. Pollard, “Autoimmune models,” in Comprehensive Toxicology, C. A. McQueen, Ed., pp. 413–438, Academic Press, Oxford, UK, 2010. View at Google Scholar
  37. P. Hultman, L. J. Bell, S. Enestrom, and K. M. Pollard, “Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic, and intra-H-2 recombinant strains,” Clinical Immunology and Immunopathology, vol. 65, no. 2, pp. 98–109, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Liu, X. Guan, and X. Ma, “Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon γ-induced RANTES/CC15 expression in macrophages,” Journal of Biological Chemistry, vol. 280, no. 26, pp. 24347–24355, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. K. M. Pollard, P. Hultman, C. B. Toomey et al., “Definition of IFN-γ-related pathways critical for chemically-induced systemic autoimmunity,” Journal of Autoimmunity, vol. 39, no. 4, pp. 323–331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Vorechovsky, J. Kralovicova, M. D. Laycock et al., “Short tandem repeat (STR) haplotypes in HLA: an integrated 50-kb STR/linkage disequilibrium/gene map between the RING3 and HLA-B genes and identification of STR haplotype diversification in the class III region,” European Journal of Human Genetics, vol. 9, no. 8, pp. 590–598, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. S. A. Tishkoff, E. Dietzsch, W. Speed et al., “Global patterns of linkage disequilibrium at the CD4 locus and modern human origins,” Science, vol. 271, no. 5254, pp. 1380–1387, 1996. View at Google Scholar · View at Scopus
  42. O. P. Kristiansen, M. Zamani, J. Johannesen et al., “Linkage and association between a CD4 gene polymorphism and IDDM in Danish IDDM patients,” Diabetes, vol. 47, no. 2, pp. 281–283, 1998. View at Google Scholar · View at Scopus
  43. M. Zamani, M. A. Tabatabaiefar, S. Mosayyebi, A. Mashaghi, and P. Mansouri, “Possible association of the CD4 gene polymorphism with vitiligo in an Iranian population: experimental dermatology,” Clinical and Experimental Dermatology, vol. 35, no. 5, pp. 521–524, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. K. M. Warpeha, W. Xu, L. Liu et al., “Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy,” FASEB Journal, vol. 13, no. 13, pp. 1825–1832, 1999. View at Google Scholar · View at Scopus